Home » DDMAC: Consumer Herceptin Video Doesn’t Balance Risk Information
DDMAC: Consumer Herceptin Video Doesn’t Balance Risk Information
The FDA has issued an untitled
letter to Genentech for a patient video that overstates the efficacy and minimizes risks of its breast cancer drug Herceptin. The consumer-directed video
fails to present information about risks associated with the chemotherapy drug with the same prominence as seen in the presentation on the drug’s effectiveness, according to the March 26 letter from the FDA’s
Division of Drug Marketing, Advertising and Communications (DDMAC).
Washington Drug Letter
Washington Drug Letter
Upcoming Events
-
07May
-
14May
-
30May